ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
2.500
+0.140 (5.93%)
At close: Oct 9, 2025, 4:00 PM EDT
2.580
+0.080 (3.20%)
Pre-market: Oct 10, 2025, 7:00 AM EDT
ProQR Therapeutics Revenue
ProQR Therapeutics had revenue of 3.98M EUR in the quarter ending June 30, 2025, a decrease of -38.48%. This brings the company's revenue in the last twelve months to 17.14M, up 8.65% year-over-year. In the year 2024, ProQR Therapeutics had annual revenue of 19.55M with 196.41% growth.
Revenue (ttm)
17.14M EUR
Revenue Growth
+8.65%
P/S Ratio
12.16
Revenue / Employee
103,191 EUR
Employees
166
Market Cap
263.36M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 19.55M | 12.95M | 196.41% |
Dec 31, 2023 | 6.59M | 2.24M | 51.27% |
Dec 31, 2022 | 4.36M | 1.98M | 83.31% |
Dec 31, 2021 | 2.38M | 1.35M | 131.10% |
Dec 31, 2020 | 1.03M | -904.00K | -46.77% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PRQR News
- 2 months ago - ProQR Announces Second Quarter 2025 Operating and Financial Results - GlobeNewsWire
- 2 months ago - ProQR Announces Upcoming Presentation at RNA Editing Summit - GlobeNewsWire
- 3 months ago - ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP - GlobeNewsWire
- 5 months ago - ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences - GlobeNewsWire
- 5 months ago - ProQR Announces First Quarter 2025 Operating and Financial Results - GlobeNewsWire
- 5 months ago - ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference - GlobeNewsWire
- 5 months ago - ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025 - GlobeNewsWire
- 6 months ago - ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth - GlobeNewsWire